$TWST
Twist Bioscience Corp
CIK:0001581280|SEC Filings
Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income (unaudited) - USD ($) shares in Thousands, $ in Thousands |
3 Months Ended | 9 Months Ended | ||||
|---|---|---|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|||
| Statement of Comprehensive Income [Abstract] | ||||||
| Revenues | [1] | $ 118,376 | $ 96,057 | $ 332,789 | $ 277,563 | |
| Costs and expenses: | ||||||
| Cost of revenues | 55,922 | 44,760 | 159,241 | 137,398 | ||
| Research and development expenses | 18,025 | 18,047 | 54,850 | 63,271 | ||
| Selling, general and administrative expenses | [1] | 80,709 | 63,370 | 226,536 | 183,219 | |
| Litigation settlement costs, net of recoveries | 0 | 0 | 7,205 | 0 | ||
| Total costs and expenses | 154,656 | 126,177 | 447,832 | 383,888 | ||
| Loss from operations | (36,280) | (30,120) | (115,043) | (106,325) | ||
| Gain on sale of business | 0 | 48,847 | 0 | 48,847 | ||
| Interest income | 1,500 | 2,690 | 5,385 | 8,731 | ||
| Other income (expense), net | [1] | 40 | (836) | 686 | (1,323) | |
| Income (loss) before income taxes | (34,740) | 20,581 | (108,972) | (50,070) | ||
| Income tax expense | (311) | (191) | (607) | (462) | ||
| Net (loss) income | (35,051) | 20,390 | (109,579) | (50,532) | ||
| Other comprehensive (loss) income: | ||||||
| Change in unrealized gain (loss) on investments | (41) | (25) | (108) | (122) | ||
| Foreign currency translation adjustment | 25 | (177) | 80 | (220) | ||
| Comprehensive (loss) income | $ (35,067) | $ 20,188 | $ (109,607) | $ (50,874) | ||
| Net (loss) income per share — basic (in usd per share) | $ (0.56) | $ 0.34 | $ (1.78) | $ (0.85) | ||
| Weighted average shares used in computing net (loss) income per share — basic (in shares) | 62,403 | 59,995 | 61,726 | 59,600 | ||
| Net (loss) income per share — diluted (in usd per share) | $ (0.56) | $ 0.33 | $ (1.78) | $ (0.85) | ||
| Weighted average shares used in computing net (loss) income per share —diluted (in shares) | 62,403 | 61,164 | 61,726 | 59,600 | ||
| ||||||
Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands |
Jun. 30, 2026 |
Sep. 30, 2025 |
||
|---|---|---|---|---|
| Current assets: | ||||
| Cash and cash equivalents | $ 117,436 | $ 183,049 | ||
| Short-term investments | 49,403 | 49,385 | ||
| Accounts receivable, net | [1] | 65,055 | 57,019 | |
| Inventories | 35,162 | 28,309 | ||
| Prepaid expenses and other current assets | [1] | 54,239 | 15,204 | |
| Total current assets | 321,295 | 332,966 | ||
| Property and equipment, net | 111,888 | 102,283 | ||
| Operating lease right-of-use assets | 68,736 | 49,377 | ||
| Investment in equity securities | [1] | 68,087 | 54,337 | |
| Goodwill | 82,195 | 82,195 | ||
| Intangible assets, net | 12,730 | 13,425 | ||
| Restricted cash, non-current | 2,130 | 2,376 | ||
| Other non-current assets | [1] | 5,376 | 4,902 | |
| Total assets | 672,437 | 641,861 | ||
| Current liabilities: | ||||
| Accounts payable | 17,043 | 11,094 | ||
| Accrued compensation | 34,879 | 31,288 | ||
| Current portion of operating lease liability | 8,630 | 13,822 | ||
| Accrued expenses and other current liabilities | 59,703 | 35,202 | ||
| Total current liabilities | 120,255 | 91,406 | ||
| Operating lease liability, net of current portion | 84,960 | 61,750 | ||
| Liability related to the sale of future revenue | 15,000 | 15,000 | ||
| Other non-current liabilities | [1] | 6,483 | 747 | |
| Total liabilities | 226,698 | 168,903 | ||
| Commitments and contingencies (Note 11) | ||||
| Stockholders’ equity | ||||
| Common stock, $0.00001 par value —200,000 and 200,000 shares authorized at June 30, 2026 and September 30, 2025, respectively; 62,674 and 60,632 shares issued and outstanding at June 30, 2026 and September 30, 2025, respectively | 1 | 0 | ||
| Additional paid-in capital | 1,875,550 | 1,793,163 | ||
| Accumulated other comprehensive loss | (655) | (627) | ||
| Accumulated deficit | (1,429,157) | (1,319,578) | ||
| Total stockholders’ equity | 445,739 | 472,958 | ||
| Total liabilities and stockholders’ equity | $ 672,437 | $ 641,861 | ||
| ||||